PRESENTED AT AACR 2024

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

download poster

Case study

Learn how HUB Organoids accelerated the preclinical oncology timeline of a bispecific to just 5 years

Quick fact

Get an overview of HUB's immuno-oncology service offering
> Read now

On-demand presentation

Discover how HUB Organoids offer a shift from a “drug centric” to a “patient-centric” approach in drug development by effectively representing a patient in the lab
> Watch more

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

FOR RESEARCH USE ONLY. Unless otherwise stated in our catalog or other company documentation
accompanying the product(s), our products are intended for research use only and are not to be used
for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro
diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to
humans or animals.